08/15/2013
Employing the power of scientific knowledge and collaborations across our global sites, we can provide developers of translational stem cell therapies with the integrated guidance and studies that are required to evaluate the safety of cellular products.
08/08/2013
We have recently expanded our expression testing offerings to now include OpenArray® technology on the QuantStudio™ 12K Flex Real-Time PCR System and can also provide genomics-based biomarker assays that can be integrated into your study design.
07/09/2013
Imaging is used routinely in clinical studies and is becoming the only truly translatable, noninvasive biomarker to human central nervous system (CNS) diseases. In addition to behavioral testing and biochemical markers, neuroanatomical and functional imaging is an inherent component of preclinical in vivo CNS efficacy studies at Charles River.
07/01/2013
Charles River has signed a worldwide sales and marketing agreement to promote and sell ImaBiotech's quantitative Mass Spectrometry Imaging (MSI) services. MSI is a new translational tool used to make more informed decisions at every step from drug discovery to preclinical development.
06/13/2013
Biomarkers support the findings from in vivo efficacy studies involving behavioral and imaging analysis and they give more in-depth information about the molecular and cellular targets that are being aimed at in various disease models. Biomarkers also aid in piecing together the translational aspects that may exist between the actual human disease and the animal model of the disease being employed.
06/10/2013
Our newest Accugenix® tech note provides insight into the various methods of fungal identification and their limitations. The need to establish an environmental monitoring program with access to a relevant and accurate microbial reference library is also discussed.
06/06/2013
Our newly validated ELISpot and FluoroSpot reader services are some of the most sensitive cellular assays available. With this technology, we now offer an even wider range of services to meet vaccine development needs.
06/03/2013
We are pleased to announce that we can now offer a seamless transition from nonclinical laboratory testing to the clinical setting due to two newly established clinical collaborations.
05/27/2013
Our newly renovated cell production laboratories with additional equipment allow for the preparation of larger quantities of primary chicken embryo fibroblasts and other cells.
05/20/2013
Our study, presented at the 2013 Experimental Biology Conference, focuses on the phenotype and genotype comparison for C57BL/6N substrains contributing to the International Mouse Phenotyping Consortium (IMPC).